Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …

Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous
thromboembolism (VTE) and major bleeding complications. Risks vary significantly between …

Thromboembolism in people with cancer still remains a major health problem and is a
leading cause of mortality after cancer itself, despite being a largely preventable disease. 1 …

PURPOSE To conduct an update of the ASCO venous thromboembolism (VTE) guideline.
METHODS After publication of potentially practice-changing clinical trials, identified through …

Patients with cancer are at higher risk of developing venous thromboembolism (VTE)
compared with the general population. This elevated risk is due to several risk factors and …

Acute thrombotic events can unveil occult cancer, as they are its first manifestation in about
20 to 30% of all cases. Malignancy interacts in an intricate way with the hemostatic system …

Cancer-associated thrombosis, with the incidence rising over the years, is associated with
significant morbidity and mortality in patients with cancer. Recent advances in the treatment …

Optimizing the anticoagulation therapy is of pivotal importance in patients with a malignant
tumor, as venous thromboembolism (VTE) has become the second-leading cause of death …

Cancer‐associated venous thromboembolism (VTE) is a leading cause of morbidity and
mortality in patients with cancer. Treatment of cancer‐associated VTE comes with a …

Opinion statement Prophylaxis and treatment of thrombosis in leukemic patients still
represent a major challenge with several clinical questions yet to be solved. Indeed, the …